MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 227 filers reported holding MYRIAD GENETICS INC in Q3 2016. The put-call ratio across all filers is 1.56 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,136 | -34.7% | 70,798 | -5.6% | 0.00% | -25.0% |
| Q2 2023 | $1,739 | -4.6% | 75,037 | -4.3% | 0.00% | 0.0% |
| Q1 2023 | $1,822 | +53.8% | 78,441 | -4.0% | 0.00% | +33.3% |
| Q4 2022 | $1,185 | -99.9% | 81,692 | 0.0% | 0.00% | -25.0% |
| Q3 2022 | $1,559,000 | +10.7% | 81,692 | +5.4% | 0.00% | +33.3% |
| Q2 2022 | $1,408,000 | -26.6% | 77,492 | +1.8% | 0.00% | -25.0% |
| Q1 2022 | $1,918,000 | +0.6% | 76,116 | +10.2% | 0.00% | 0.0% |
| Q4 2021 | $1,907,000 | -13.5% | 69,098 | +1.2% | 0.00% | -20.0% |
| Q3 2021 | $2,205,000 | +5.6% | 68,298 | 0.0% | 0.01% | +25.0% |
| Q2 2021 | $2,089,000 | +0.4% | 68,298 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $2,080,000 | +63.8% | 68,298 | +6.4% | 0.00% | +33.3% |
| Q4 2020 | $1,270,000 | +51.7% | 64,198 | 0.0% | 0.00% | +50.0% |
| Q3 2020 | $837,000 | +10.9% | 64,198 | -3.6% | 0.00% | 0.0% |
| Q2 2020 | $755,000 | -24.0% | 66,598 | -4.0% | 0.00% | -33.3% |
| Q1 2020 | $993,000 | -50.6% | 69,398 | -6.1% | 0.00% | -40.0% |
| Q4 2019 | $2,012,000 | +32.9% | 73,898 | +39.7% | 0.01% | +25.0% |
| Q3 2019 | $1,514,000 | +7.5% | 52,898 | +4.3% | 0.00% | 0.0% |
| Q2 2019 | $1,408,000 | -16.5% | 50,698 | -0.2% | 0.00% | 0.0% |
| Q1 2019 | $1,686,000 | +14.9% | 50,798 | +0.6% | 0.00% | 0.0% |
| Q4 2018 | $1,468,000 | -34.3% | 50,491 | +3.9% | 0.00% | -20.0% |
| Q3 2018 | $2,236,000 | +23.3% | 48,616 | +0.2% | 0.01% | +25.0% |
| Q2 2018 | $1,813,000 | +28.3% | 48,516 | +1.4% | 0.00% | +33.3% |
| Q1 2018 | $1,413,000 | -13.8% | 47,831 | +0.2% | 0.00% | -25.0% |
| Q4 2017 | $1,639,000 | +26.6% | 47,731 | +33.3% | 0.00% | +33.3% |
| Q3 2017 | $1,295,000 | +82.9% | 35,800 | +30.7% | 0.00% | +50.0% |
| Q2 2017 | $708,000 | +40.8% | 27,400 | +4.6% | 0.00% | +100.0% |
| Q1 2017 | $503,000 | +322.7% | 26,200 | +351.7% | 0.00% | – |
| Q3 2016 | $119,000 | -35.3% | 5,800 | -3.3% | 0.00% | – |
| Q2 2016 | $184,000 | -18.2% | 6,000 | 0.0% | 0.00% | -100.0% |
| Q1 2016 | $225,000 | – | 6,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,750,000 | $75,900,000 | 2.61% |
| PFM Health Sciences, LP | 2,025,681 | $55,909,000 | 1.90% |
| Tieton Capital Management, LLC | 118,456 | $3,269,000 | 1.83% |
| Altium Capital Management LP | 190,000 | $5,244,000 | 1.45% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,846,490 | $50,963,000 | 1.03% |
| EARNEST PARTNERS LLC | 6,316,365 | $174,332,000 | 1.01% |
| Glenview Capital Management | 1,679,747 | $46,361,000 | 0.99% |
| Zebra Capital Management LLC | 14,209 | $392,000 | 0.63% |
| AIMZ Investment Advisors, LLC | 44,185 | $1,220,000 | 0.48% |
| Phocas Financial Corp. | 132,101 | $3,646,000 | 0.46% |